Radiation promotes malignant phenotypes through SRC in breast cancer cells

Area of Science:

• Oncology
• Molecular Biology
• Radiotherapy Research

Background:

• Ionizing radiation (IR) is a standard breast cancer treatment.
• Evidence suggests IR can paradoxically promote cancer malignancy.
• Molecular mechanisms of radiation-induced cancer progression are not fully understood.

Purpose of the Study:

• Investigate the molecular mechanisms of radiation-induced breast cancer progression.
• Determine the role of SRC signaling in radiation-induced malignant phenotypes.
• Evaluate SRC inhibition as a therapeutic strategy in breast cancer.

Main Methods:

• Irradiation of breast cancer cells.
• Analysis of SRC family kinase activation.
• Assessment of invasiveness, cancer stem-like cell population, and drug resistance.
• Inhibition of SRC, phosphatidylinositol 3-kinase/protein kinase B, and p38 MAPK signaling pathways.
• Evaluation of epithelial-mesenchymal transition (EMT) and SLUG expression.

Main Results:

• Irradiation activates SRC signaling in breast cancer cells.
• Activated SRC promotes invasiveness, expansion of cancer stem-like cells, and resistance to anticancer agents.
• Radiation-activated SRC induces SLUG expression and EMT via PI3K/Akt and p38 MAPK pathways.
• Inhibition of SRC or its downstream pathways attenuates radiation-induced EMT and stem-like cell increase.
• SRC downregulation abolishes radiation-acquired resistance to cisplatin, etoposide, paclitaxel, and IR.

Conclusions:

• SRC signaling is a key mediator of radiation-induced breast cancer progression.
• Targeting SRC signaling can attenuate harmful radiation effects and enhance treatment efficacy.
• Combining radiotherapy with SRC inhibition is a promising strategy for breast cancer treatment.